Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 3:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 39 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Open Radical Prostatectomy Clear all
Active, not recruiting Phase 2Phase 3 Interventional

AMNIOX CORD Study - Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft

NCT04263025
View directory record Official record
Conditions
Prostate Cancer
Interventions
Cryopreserved Umbilical Cord Allograft, Robot-Assisted Radical Prostatectomy
Biological · Procedure
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
30 Years to 70 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 13, 2026, 3:35 AM EDT
Active, not recruiting Not applicable Interventional

A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer

NCT05027477
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Radical Prostatectomy, TULSA Procedure
Device
Lead sponsor
Profound Medical Inc.
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2036
U.S. locations
19
States / cities
Chandler, Arizona • Mesa, Arizona • Scottsdale, Arizona + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced Sep 13, 2026, 3:35 AM EDT
Terminated Phase 2 Interventional Results available

Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer

NCT03964337
View directory record Official record
Conditions
Prostate Cancer, Prostate Cancer Adenocarcinoma, Non-Metastatic
Interventions
Cabozantinib, Radical Prostatectomy
Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Sep 13, 2026, 3:35 AM EDT
Completed Phase 3 Interventional Results available

Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer

NCT03739684
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Recurrent, Prostate Cancer Metastatic
Interventions
18F-DCFPyL, PET/CT Imaging
Drug · Diagnostic Test
Lead sponsor
Progenics Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
13
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 13, 2026, 3:35 AM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

NCT03821246
View directory record Official record
Conditions
Prostate Adenocarcinoma, Prostate Cancer, Localized Prostate Cancer
Interventions
Atezolizumab, Tocilizumab, Etrumadenant
Drug
Lead sponsor
David Oh
Other
Eligibility
18 Years and older · Male only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
San Francisco, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 13, 2026, 3:35 AM EDT
Completed Phase 1 Interventional

A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.

NCT05938270
View directory record Official record
Conditions
Prostate Cancer
Interventions
Saruparib (AZD5305), Darolutamide, No Treatment
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Detroit, Michigan • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 13, 2026, 3:35 AM EDT
Completed Not applicable Interventional Results available

A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine

NCT01992016
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Bone Metastases, Soft Tissue Metastases, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
Ranolazine
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
19 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 2, 2018 · Synced Sep 13, 2026, 3:35 AM EDT
Completed Phase 3 Interventional Results available

Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy

NCT00283062
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Docetaxel (TAXOTERE®) Chemotherapy, Leuprolide acetate ( ELIGARD®) Hormonal Therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Male only
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 25, 2012 · Synced Sep 13, 2026, 3:35 AM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer

NCT02506114
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
PROSTVAC V/F, Ipilimumab
Biological · Drug
Lead sponsor
Lawrence Fong
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Sep 13, 2026, 3:35 AM EDT
Recruiting Phase 1 Interventional

Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy

NCT06450106
View directory record Official record
Conditions
Prostate Cancer
Interventions
STM-416p
Drug
Lead sponsor
SURGE Therapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Tucson, Arizona • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 13, 2026, 3:35 AM EDT
Active, not recruiting Phase 2 Interventional

Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer

NCT05241340
View directory record Official record
Conditions
Urothelial Carcinoma Bladder
Interventions
Sasanlimab, Stereotactic Body Radiation Therapy, Radical Cystectomy + pelvic lymph node dissection + urinary diversion
Drug · Radiation · Procedure
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 13, 2026, 3:35 AM EDT
Terminated Not applicable Interventional Results available

Phase II Investigation of Prostate Artery Embolization (PAE) Before Radical Prostatectomy in Prostate Cancer Patients

NCT02173522
View directory record Official record
Conditions
Prostate Cancer
Interventions
Prostate artery embolization (PAE)
Device
Lead sponsor
Shivank Bhatia
Other
Eligibility
45 Years to 79 Years · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Sep 13, 2026, 3:35 AM EDT
Active, not recruiting Phase 2 Interventional

Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer

NCT01990196
View directory record Official record
Conditions
Prostate Cancer
Interventions
degarelix, enzalutamide, trametinib, dasatinib
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced Sep 13, 2026, 3:35 AM EDT
Completed Phase 2 Interventional Results available

Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer

NCT01088529
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone Acetate, Prednisone, LHRHa
Drug
Lead sponsor
Cougar Biotechnology, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Sep 13, 2026, 3:35 AM EDT
Terminated Not applicable Interventional Results available

Pharmacological Penile Rehabilitation in the Preservation of Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy

NCT00955929
View directory record Official record
Conditions
Penile Cancer, Erectile Dysfunction, Radical Prostatectomy
Interventions
Placebo QHS and sildenafil and questionnaires, Sildenafil and questionnaire, Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Sep 13, 2026, 3:35 AM EDT
Completed Phase 1 Interventional

Copper Cu 64 TP3805 PET in Detecting Cancer in Patients With Prostate Cancer Undergoing Surgery

NCT02603965
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
Copper Cu 64 TP3805, Positron Emission Tomography, Computed Tomography, Radical Prostatectomy, Laboratory Biomarker Analysis
Radiation · Procedure · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
21 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Sep 13, 2026, 3:35 AM EDT
Terminated Not applicable Interventional Results available

CivaSheet With Radical Prostatectomy & Adjuvant External Beam Radiation

NCT03657108
View directory record Official record
Conditions
Prostate Cancer
Interventions
Civasheet 60 Gy, Civasheet 75 Gy, Adjuvant external beam radiation therapy
Radiation
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Sep 13, 2026, 3:35 AM EDT
Terminated Phase 4 Interventional

Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy

NCT01365143
View directory record Official record
Conditions
Prostatic Neoplasms, Adenocarcinoma
Interventions
Robotic Radical Prostatectomy, Open Radical Prostatectomy
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 1, 2014 · Synced Sep 13, 2026, 3:35 AM EDT
Completed Not applicable Interventional Results available

REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery

NCT02073162
View directory record Official record
Conditions
Major Abdominal Surgery
Interventions
Major Abdominal Surgery
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Sep 13, 2026, 3:35 AM EDT
Withdrawn Phase 3 Interventional

BioDFence® G3 For Full Nerve-Sparing Robotic-Assisted Radical Prostatectomy

NCT05363644
View directory record Official record
Conditions
Prostate Cancer, Prostatectomy, Erectile Dysfunction Following Radical Prostatectomy, Incontinence, Urinary
Interventions
BioDFence G3
Biological
Lead sponsor
AdventHealth
Other
Eligibility
40 Years to 70 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Celebration, Florida
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Sep 13, 2026, 3:35 AM EDT
Completed Phase 2 Interventional

Neoadjuvant CCI-779 Followed By Radical Prostatectomy in Treating Patients With Newly Diagnosed Prostate Cancer Who Have a High Risk of Relapse

NCT00071968
View directory record Official record
Conditions
Prostate Cancer
Interventions
temsirolimus, conventional surgery, neoadjuvant therapy
Drug · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Sep 13, 2026, 3:35 AM EDT
Recruiting Phase 2 Interventional

FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer

NCT06636682
View directory record Official record
Conditions
Prostate Cancer (Adenocarcinoma), Prostate CA, Prostate Cancers, Prostate Cancer (Post Prostatectomy), Prostate Cancer, Prostate Cancer Patients Undergoing Radical Prostatectomy, High-risk Prostate Cancer
Interventions
FK-PC101, Standard of Care (SOC)
Biological
Lead sponsor
Cellvax Therapeutics Inc
Industry
Eligibility
Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Chicago, Illinois • Gahanna, Ohio • Myrtle Beach, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 20, 2024 · Synced Sep 13, 2026, 3:35 AM EDT
Completed Phase 2 Interventional Results available

A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases

NCT04523207
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Apalutamide, ADT, Relugolix
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
32
States / cities
Tucson, Arizona • Little Rock, Arkansas • Sherman Oaks, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 13, 2026, 3:35 AM EDT
Withdrawn Phase 2 Interventional

Study of Metformin With Simvastatin for Men With Prostate Carcinoma

NCT01561482
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Metformin, Simvastatin
Drug
Lead sponsor
Nicholas Mitsiades
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2015 · Synced Sep 13, 2026, 3:35 AM EDT